Polyrizon Ltd. Ordinary Shares (PLRZ) - Total Liabilities
Based on the latest financial reports, Polyrizon Ltd. Ordinary Shares (PLRZ) has total liabilities worth $364.00K USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Polyrizon Ltd. Ordinary Shares generate cash to assess how effectively this company generates cash.
Polyrizon Ltd. Ordinary Shares - Total Liabilities Trend (2020–2024)
This chart illustrates how Polyrizon Ltd. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Polyrizon Ltd. Ordinary Shares's assets to evaluate the company's liquid asset resilience ratio.
Polyrizon Ltd. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Polyrizon Ltd. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hampton Financial Corp
V:HFC
|
Canada | CA$26.32 Million |
|
Omineca Mining and Metals Ltd
V:OMM
|
Canada | CA$13.59 Million |
|
CAM Resources Bhd
KLSE:7128
|
Malaysia | RM40.27 Million |
|
Voyageur Pharmaceuticals Ltd
V:VM
|
Canada | CA$1.85 Million |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
USA | $338.49 Million |
|
Grand Baoxin Auto Group Limited
F:6BA
|
Germany | €13.46 Billion |
|
Vo2 Cap Holding AB
ST:VO2
|
Sweden | Skr122.46 Million |
|
Klimator AB
ST:KLIMAT
|
Sweden | Skr17.80 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Polyrizon Ltd. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Polyrizon Ltd. Ordinary Shares.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 44.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Polyrizon Ltd. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Polyrizon Ltd. Ordinary Shares (2020–2024)
The table below shows the annual total liabilities of Polyrizon Ltd. Ordinary Shares from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $261.00K | -65.20% |
| 2023-12-31 | $750.00K | -37.40% |
| 2022-12-31 | $1.20 Million | +73.62% |
| 2021-12-31 | $690.00K | +8525.00% |
| 2020-12-31 | $8.00K | -- |
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nas… Read more